US · PACB · MEDICAL - DEVICES
Pacific Biosciences of California, Inc. (PACB) intrinsic value and stock valuation
$1.63as of 2026-11-21 · Mkt cap 403.78M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Pacific Biosciences of California, Inc. DCF and intrinsic value
InvestorsCraft values PACB with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PACB’s statements →
Pacific Biosciences of California, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Butterfly Network, Inc. (BFLY) $5.40
- Iovance Biotherapeutics, Inc. (IOVA) $6.90
- Integra LifeSciences Holdings Corporation (IART) $13.25
- SI-BONE, Inc. (SIBN) $23.73
- Ginkgo Bioworks Holdings, Inc. (DNA) $7.46
- Fulgent Genetics, Inc. (FLGT) $24.12
- Orthofix Medical Inc. (OFIX) $6.07
- DarioHealth Corp. (DRIO) $1.32
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $160M | $154M | $200.5M | $128.3M | $130.5M |
| Operating income | -$-557.56M | -$-474.31M | -$-334.47M | -$-307.2M | -$-210.44M |
| Net income | -$-546.38M | -$-309.85M | -$-306.74M | -$-314.25M | -$-181.22M |
| EPSd | -$-1.82M | -$-1.07M | -$-1.21M | -$-1.4M | -$-887.72K |
| Operating cash flow | -$-111.21M | -$-206.06M | -$-266.55M | -$-263.21M | -$-111.18M |
| Capital expenditure | -$-2.71M | -$-6.19M | -$-8.84M | -$-16.93M | -$-5.93M |
| Free cash flow | -$-113.92M | -$-212.25M | -$-275.39M | -$-280.14M | -$-117.11M |
| Total assets | $784.1M | $1.26B | $1.75B | $1.77B | $2.01B |
| Total debt | $759.5M | $672.4M | $933.9M | $948.5M | $955.4M |
| Net debt | $695.8M | $617.1M | $754M | $623.4M | $494.6M |
| Total equity | $5.35M | $506.6M | $701.3M | $562.9M | $791M |
| Cash and short-term investments | $279.5M | $389.9M | $631.4M | $772.3M | $1.04B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $160M | $154M | $200.5M | $128.3M | $130.5M |
| Cost of revenue | $109.3M | $116.7M | $147.7M | $79.3M | $71.7M |
| Gross profit | $50.7M | $37.3M | $52.8M | $49M | $58.9M |
| Research and development expenses | $97.3M | $134.9M | $187.2M | $193M | $112.9M |
| Selling, general and administrative expenses | $141.5M | $175M | $169.8M | $160.9M | $124.1M |
| Other expenses | $369.4M | $201.7M | $30.3M | $2.38M | $32.3M |
| Operating expenses | $608.2M | $511.6M | $387.3M | $356.2M | $269.3M |
| Cost and expenses | $717.6M | $628.3M | $535M | $435.5M | $341M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $6.95M | $13.4M | $14.3M | $14.7M | $12.5M |
| Depreciation and amortization | $504.9M | $53.4M | $32.7M | $17.3M | $11.6M |
| Ebitda | -$-34.2M | -$-242.77M | -$-271.12M | -$-282.24M | -$-250.76M |
| Operating income | -$-557.56M | -$-474.31M | -$-334.47M | -$-307.2M | -$-210.44M |
| Total other income/expenses, net | $11.5M | $164.8M | $16.3M | -$-7.05M | -$-64.44M |
| Income before tax | -$-546.06M | -$-309.54M | -$-318.16M | -$-314.25M | -$-274.87M |
| Income tax expense | $320K | $320K | -$-11.42M | $0.00 | -$-93.65M |
| Net income | -$-546.38M | -$-309.85M | -$-306.74M | -$-314.25M | -$-181.22M |
| Weighted average shares outstanding | $300M | $274.5M | $253.6M | $224.6M | $203.6M |
| Weighted average diluted shares outstanding | $300M | $288.4M | $253.6M | $224.6M | $204.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $279.5M | $389.9M | $631.4M | $772.3M | $1.04B |
| Net receivables | $35.5M | $27.5M | $36.6M | $18.8M | $24.2M |
| Inventory | $49.3M | $58.8M | $56.7M | $50.4M | $24.6M |
| Total current assets | $375M | $495.7M | $742.1M | $852.1M | $1.1B |
| Property, plant and equipment, net | $65.8M | $46.6M | $69M | $81.3M | $79.1M |
| Goodwill and intangible assets | $332.9M | $707.3M | $919.3M | $820.2M | $821M |
| Long-term investments | $1.53M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $409.1M | $764.8M | $1B | $915M | $905.8M |
| Total assets | $784.1M | $1.26B | $1.75B | $1.77B | $2.01B |
| Accounts payable | $20.8M | $16.6M | $15.1M | $12M | $11M |
| Short-term debt | $900K | $10M | $10.1M | $10.7M | $9.32M |
| Deferred revenue | $0.00 | $13.9M | $16.3M | $30.5M | $11M |
| Total current liabilities | $54.4M | $66.3M | $95M | $263.3M | $71.7M |
| Long-term debt | $759.5M | $662.4M | $923.9M | $937.8M | $946M |
| Deferred revenue, non-current | $19.9M | $5.9M | $5.53M | $1.79M | $25.1M |
| Total non-current liabilities | $724.3M | $687.6M | $949.7M | $940.9M | $1.14B |
| Capital lease obligations | $57.5M | $24.9M | $41.2M | $50M | $57.7M |
| Total liabilities | $778.7M | $753.9M | $1.04B | $1.2B | $1.22B |
| Common stock | $300K | $290K | $270K | $230K | $220K |
| Retained earnings | -$-2.7B | -$-2.15B | -$-1.84B | -$-1.53B | -$-1.22B |
| Accumulated other comprehensive income (loss) | $460K | $420K | $220K | -$-4.76M | -$-1.09M |
| Total equity | $5.35M | $506.6M | $701.3M | $562.9M | $791M |
| Total investments | $217.3M | $334.6M | $451.5M | $447.2M | $583.7M |
| Total debt | $759.5M | $672.4M | $933.9M | $948.5M | $955.4M |
| Net debt | $695.8M | $617.1M | $754M | $623.4M | $494.6M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-546.38M | -$-309.85M | -$-306.74M | -$-314.25M | -$-181.22M |
| Depreciation and amortization | $386.4M | $53.3M | $32.7M | $17.3M | $11.6M |
| Stock-based compensation | $41.7M | $0.00 | $0.00 | $78.6M | $80.7M |
| Change in working capital | $4.44M | -$-40.58M | -$-58.96M | -$-53.97M | $21M |
| Accounts receivable | -$-7.92M | $9.09M | -$-17.83M | $5.46M | -$-7.17M |
| Inventory | -$-1.42M | -$-8.32M | -$-13.84M | -$-33.91M | -$-12.43M |
| Accounts payable | $2.48M | $1.41M | $210K | $1.02M | $6.36M |
| Net cash provided by operating activities | -$-111.21M | -$-206.06M | -$-266.55M | -$-263.21M | -$-111.18M |
| Investments in property, plant and equipment | -$-2.71M | -$-6.19M | -$-8.84M | -$-16.93M | -$-5.93M |
| Acquisitions, net | $0.00 | $0.00 | -$-100K | $180K | -$-319.79M |
| Net cash used for investing activities | $115.5M | $124M | $4.6M | $116.1M | -$-678.53M |
| Common stock issued | $3.43M | $7.7M | $204.5M | $11.2M | $294.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $3.43M | -$-42.99M | $116.3M | $9.62M | $1.17B |
| Net change in cash | $7.67M | -$-124.15M | -$-145.18M | -$-137.51M | $379.9M |
| Cash at end of period | $63.7M | $56.1M | $180.2M | $328.3M | $465.8M |
| Operating cash flow | -$-111.21M | -$-206.06M | -$-266.55M | -$-263.21M | -$-111.18M |
| Capital expenditure | -$-2.71M | -$-6.19M | -$-8.84M | -$-16.93M | -$-5.93M |
| Free cash flow | -$-113.92M | -$-212.25M | -$-275.39M | -$-280.14M | -$-117.11M |
Line items
Line items
Line items
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
- CEO
- Christian O. Henry
- Employees
- 485
- Beta
- 2.29
Explore
Frequently asked questions
What is the intrinsic value of Pacific Biosciences of California, Inc. (PACB)?
Pacific Biosciences of California, Inc. (PACB) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PACB undervalued?
PACB trades at a price of $1.63 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.